Strong Financial Performance in Q1

GSK plc has announced a notable financial performance for the first quarter of 2023, with turnover reaching £6.95 billion. This marks a 2% increase compared to the same period in 2024, or a 4% rise at a constant exchange rate.

Significant Growth in Earnings

The company reported a remarkable 55% year-on-year surge in total earnings per share (EPS) to 39.7 pence, while core EPS experienced a 4% increase to 44.9 pence. Operating profit also saw a substantial rise, jumping 49% to £2.2 billion from the first quarter of 2024, with adjusted operating profit climbing 4% to £2.5 billion.

Leadership's Perspective

Emma Walmsley, CEO of GSK, expressed optimism about the company's trajectory, stating, "GSK continues to make strong progress, demonstrating the quality, strength, and resilience of our portfolio. Our Specialty Medicines business, the largest segment, contributed significantly to sales this quarter." She also highlighted advancements in R&D, including FDA approvals and the acquisition of a promising oncology asset, alongside preparations for upcoming product launches in respiratory, oncology, HIV, and hepatitis treatments.